Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ZN-d5 / Zentalis Pharma
ZN-d5-004C, NCT05682170: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) Jul 2024 - Dec 2024 : Preliminary data r/r/ AML	Terminated	1/2	40	US	ZN-d5 ZN-c3, Study Drug, ZN-c3	K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.	Acute Myeloid Leukemia (AML)	07/24	07/24
ZN-d5-003, NCT05199337 / 2021-003008-42: Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis	Completed	1/2	18	Europe, US, RoW	ZN-d5, Study Drug	K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc., K-Group Alpha, Inc	Amyloidosis, AL Amyloidosis	02/24	02/24
ZN-d5-002, NCT04854174: A Food Effect Study of ZN-d5 in Healthy Female Volunteers	Completed	1	16	RoW	ZN-d5, Study Drug	K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.	Healthy Volunteers	06/21	07/21
NCT05127811: A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma	Terminated	1	8	RoW	ZN-d5	Zentera Therapeutics HK Limited	Non-Hodgkin Lymphoma	05/23	05/23
ZN-d5-001, NCT04500587: Phase 1 First in Human Study of ZN-d5 as a Single Agent	Completed	1	39	Europe, RoW	ZN-d5, Study Drug	K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.	Acute Myeloid Leukemia, Non Hodgkin Lymphoma	12/23	12/23